Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
What chemotherapy regimen would you use for a woman with pre-existing neuropathy causing imbalance, who now has a T1N0 ER+ and Her2+ breast cancer?
Answer from: Medical Oncologist at Community Practice
If the tumor is T1c, you can consider AC x4. Afterwards, single-agent Herceptin could be considered.
Sign In
or
Register
to read more
17705
Related Questions
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What are your top takeaways in Breast Cancer from ASCO 2025?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
What are your top takeaways in Radiation Oncology from SABCS 2024?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Would you discontinue tamoxifen for endometrial hyperplasia without dysplasia in the adjuvant setting?
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?